ClinicalTrials.gg
CompletedNCT03989778Updated Oct 29, 2026

Vitamin D and Polycystic Ovarian Syndrome (PCOS)

An Early Phase 1 interventional study of Vitamin D in Infertility, Female, Infertility and Vitamin D Deficiency, sponsored by Aga Khan University. Completed at 2 sites in Pakistan. Open to participants aged 18 Years to 36 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Aga Khan University · Early Phase 1, Interventional, and Health services research

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 36 Years
Sex
All
01

Study summary

Primary Objectives:

To evaluate the efficacy of metformin and Vitamin D supplementation on serum insulin and serum androgen levels (Total testosterone, Steroid Hormone Binding Globulin, Free Androgen Index) levels compared metformin alone in infertile Poly cystic ovarian females of reproductive age group.

Secondary Objectives:

To measure change in endometrial thickness/number of follicles and follicular size by day 12 trans-vaginal ultrasound in the intervention group i.e. combination of metformin and vitamin D supplementation

Read the detailed description

Polycystic ovary syndrome (PCOS) as defined by "the presence of any two out of three criteria i.e. Oligo and/or anovulation, excess androgen activity and/or polycystic ovarian morphology on ultrasound", is a prevalent cause of female infertility. In the endocrine milieu of PCOS higher levels of insulin due to insulin resistance (IR) exert direct effects on the ovaries, release insulin-like growth factor 1 (IGF-1) from the liver and both then increase levels of testosterone. The resultant prevents the growth of ovarian follicles to acquire the required dimension for ovulation (i.e. > 10 mm) hence leading to anovulation and therefore subfertility. Vitamin D (VD) has found to be predominantly deficient in PCOS females, documented to cause IR giving rise to anovulatory cycles, hyperandrogenism and other significant features of PCOS. Therefore, we have hypothesized that treatment with VD in PCOS females can reduce IR, improve ovulation and signs of hyperandrogenism. Since Metformin is frequently prescribed for reducing IR and hence the treatment for anovulatory infertility in these females, we have planned to conduct an open label randomized control trial in PCOS infertile females who have vitamin D levels \< than 25 ng/ml and are receiving Metformin therapy after ethical approval from Aga Khan University. The intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas control group will receive Metformin treatment during the study period. We will compare change in number of dominant follicles (more than 10 mm) / endometrial thickness in both groups by Day 12 trans-vaginal ultrasound at the time of enrollment with scans done after 12 and 24 weeks. The other biochemical parameters [Total Testosterone, Steroid Hormone Binding Globulin, Free Androgen Index, Lipid Accumulation Product, Serum Insulin, Serum Triglycerides, Serum Calcium and Albumin] will be done at the time of recruitment in both the intervention and control groups and compared.

02

Conditions studied

  • Infertility, Female
  • Infertility
  • Vitamin D Deficiency
03

In context

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

This study's enrollment of 84 is below the median of 100 across 378 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

Aga Khan University is the lead sponsor of 294 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 36 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females with age range 18- 36 years, from all ethnic background having primary infertility with diagnosis of PCOS when at least 2 of these 3 elements are present: hyperandrogenism, chronic anovulation and polycystic ovaries and Vitamin D deficiency serum levels \< 25 nmol/L

Exclusion criteria

Exclusion Criteria:

exclusion criteria at baseline will be excluded from the study

  • Females with secondary Infertility
  • Hypercalcemia (plasma calcium concentrations> 2.65 mmol/L)
  • Exclude women with Tuberculosis or other granulomatous disorders.
  • Women receiving vitamin D replacement, oral , hormonal replacement therapy, , calcium supplementation, insulin-sensitizing drugs(incretin mimetic drugs, thiazolidinedione, sulfonylurea), lipid-lowering drugs or other drugs affecting insulin sensitivity or serum androgens (e.g., niacin, corticosteroids, beta-blockers, calcium channel blockers, thiazide diuretics), anti-epileptics, anti-retroviral, cholestyramine, anti-fungal, statins, H2 blockers, , chemotherapeutic agents, antimicrobials (Rifampicin, isoniazid, hydroqychloroquin) or any other drug modifying lipid metabolism in the previous 3 months prior to study
  • Women with congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, type 2 diabetes mellitus, renal, hepatic or thyroid disorders, hyperparathyroidism, malabsorption syndromes, Chronic Kidney Disease Hepatic failure, cystic fibrosis, vaginal bleeding of unknown etiology Women Those who had Bariatric surgery will also be excluded.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Early Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Vitamin D supplement

    The intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas

    Drug: Vitamin D

  • No intervention
    Control

    control group will receive Metformin treatment during the study period.

Interventions

  • Vitamin D supplementation

    Also known as: Metformin

06

What researchers measure

Primary outcomes

  1. • Insulin levels

    Decrease in insulin levels 60%

    Time frame: 24 weeks

  2. • serum androgen levels

    Decrease in Serum Androgen levels

    Time frame: 24 weeks

Secondary outcomes

  1. Endometrial thickness

    increase in endometrial thickness to 2mm

    Time frame: 24 weeks

  2. Lipid Accumulation Product

    reduction in lipid accumulation product

    Time frame: 24 weeks

07

Study locations

2 sites
  • Dr Rehana Rehman
    Karachi, Sindh 74800, Pakistan
  • Dr Rehana Rehman
    Karachi, Sindh 75500, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Oct 2026, 44 months.

Of 15 phase 1 interventional studies under Infertility, Female, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 44 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jun 2025 → Oct 2026 and completion Jul 2025 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2019
First posted
Jun 18, 2019
StartActual
Feb 1, 2023
Primary completionActual
Oct 10, 2026was Jun 2025
CompletionActual
Oct 15, 2026was Jul 2025
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Primary completion
Jun 30, 2025→Oct 10, 2026 (actual)
Oct 29, 2026
Study completion
Jul 13, 2025→Oct 15, 2026 (actual)
Oct 29, 2026
Enrollment
300 (estimated)→84 (actual)
Oct 29, 2026
Design
Phase 2→Early Phase 1
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    Primary completion Jun 30, 2025→Oct 10, 2026 (now actual)
    Study completion Jul 13, 2025→Oct 15, 2026 (now actual)
    Enrollment 300 (estimated)→84 (actual)
    Design Phase 2→Early Phase 1
    + 3 other changes: index terms, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03989778
Responsible party
Rehana Rehman (Associate Professor, Aga Khan University) — Principal investigator
First posted
Jun 18, 2019
Start date
Feb 1, 2023
Primary completion
Oct 10, 2026
Completion
Oct 15, 2026
Last update
Oct 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin D

Start the discussion